Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Wolfgang P. Fendler, Waldemar Uhl et al.|Journal of Nuclear Medicine|2022Cited by 68
<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the<sup>68</sup>Ga-FAPI PET Observational TrialLukas Kessler, Jens T. Siveke, Ken Herrmann et al.|Journal of Nuclear Medicine|2023Cited by 34
Diagnostic Accuracy of<sup>68</sup>Ga-FAPI Versus<sup>18</sup>F-FDG PET in Patients with Various MalignanciesNader Hirmas, Wolfgang P. Fendler, Martin Glas et al.|Journal of Nuclear Medicine|2024Cited by 31
Prognostic Implications of<sup>68</sup>Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid TumorsMasao Watanabe, Manuel Weber, Viktor Grünwald et al.|Journal of Nuclear Medicine|2024Cited by 18
Head-to-head comparison of 68 Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumorsMasao Watanabe, Manuel Weber, Viktor Grünwald et al.|Annals of Nuclear Medicine|2024Cited by 15